Bruce Wendel - 12 Dec 2025 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role: Director
Signature: /s/ Philip LoScalzo, as Attorney-in-Fact
Issuer symbol: IBRX
Transactions as of: 12 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 16 Dec 2025, 17:55:49 UTC
Previous filing: 01 Feb 2023
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wendel Bruce	Director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO	/s/ Philip LoScalzo, as Attorney-in-Fact	16 Dec 2025	0001364846

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IBRX	Stock Option (right to buy)	Award	$0	+146,020		$0.000000	146,020	12 Dec 2025	Common Stock	146,020	$2.36	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Subject to the reporting person's continuing to be a Service Provider (as defined in the 2025 Equity Incentive Plan) through each applicable vesting date, 48,673 of the shares subject to the award will vest on December 12, 2026, 48,673 of the shares subject to the award will vest on December 12, 2027 and 48,674 of the shares subject to the award will vest on December 12, 2028, such that the award will be fully vested on December 12, 2028; provided that, notwithstanding the foregoing, any unvested shares subject to the award will fully vest immediately prior to a Change in Control (as defined in the 2025 Equity Incentive Plan), subject to the reporting person continuing to be a Service Provider through the date of such Change in Control.

Content

Subject to the reporting person's continuing to be a Service Provider (as defined in the 2025 Equity Incentive Plan) through each applicable vesting date, 48,673 of the shares subject to the award will vest on December 12, 2026, 48,673 of the shares subject to the award will vest on December 12, 2027 and 48,674 of the shares subject to the award will vest on December 12, 2028, such that the award will be fully vested on December 12, 2028; provided that, notwithstanding the foregoing, any unvested shares subject to the award will fully vest immediately prior to a Change in Control (as defined in the 2025 Equity Incentive Plan), subject to the reporting person continuing to be a Service Provider through the date of such Change in Control.